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ABSTRACT
Effective therapies exist for the treatment of both vaginal trichomoniasis and bacterial vaginosis
(BV). Recurrent trichomonas infection is uncommon, and significant metronidazole resistance
remains rare. The management of metronidazole-resistant trichomoniasis is dependent on susceptibility studies, which can be used to guide higher doses of metronidazole therapy. Recurrent B V is
common. A mechanism for reestablishing the normal vaginal flora with H202-producing lactobacilli
remains elusive. The management of this recurrent infection is based upon a longer duration of
therapy with currently available antibiotic regimens and documentation of a clinical response using
composite clinical criteria and Gram’s stain of the vaginal secretions. (C) 1995 Wiley-Liss, Inc.
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is one of the most common problems in
clinical medicine, accounting for more than 10
million office visits each year. It is the most common reason for a patient to visit her obstetriciangynecologist. Bacterial vaginosis (BV) and vaginal
trichomoniasis are 2 of the most common causes of
infective vaginitis. While effective therapy for these
diseases exists, recurrent disease is not uncommon.
Crucial management strategies for patients with
recurrent disease include confirmation of the diagnosis and clinical monitoring of the disorder while
the patient undergoes antimicrobial therapy.
aginitis

a single 2-g dose; these regimens have median cure
rates of 92% and 96%, respectively. 3 Treatment
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failures have been attributed to noncompliance with
therapy, reinfection, or in situ inactivation or malabsorption of the drug. 4-6 Although metronidazole
resistance is increasing, it is still uncommon. 7
The 2-g single-dose regimen minimizes noncompliance and is more practical for the treatment
of sexual partners. Sexual partners should be treated
since reinfection rates of 6.2% to 23.7% are noted
in women whose sexual partners are not treated
simultaneously. 6-8 In addition, T. vaginalis can be
a cause of tetracycline-resistant nongonococcal urethritis in males.

Trichomonas vaginalis is one of the most common
organisms causing vaginitis in women worldwide
and affects approximately 3 million American
women annually. 2 Metronidazole remains the drug
of choice for the treatment of trichomonas vaginitis. The most extensively studied metronidazole regimens have been 200-250 mg t.i.d, for 7 days and

Recommended Regimens
Metronidazole is the only trichomonacidal drug
available in the United States. Metronidazole, 2 g
orally in a single dose, is the current recommended
regimen for the treatment of both men and women
with trichomoniasis. 9 An alternative regimen is
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TABLE I. Treatment of metronidazole-resistant trichomoniasis
Resistance
level
Marginal

Low
Moderate
High
High (alternate)

Aerobic MLC

(lg/ml)
50

< 100
100-200
> 200

Metronidazole
regimen

Retreatment with standard dose
2 g qd for 3-5 days
2-2.5 g qd for 7-10 days
3-3.5 g qd for 14-18 days
2 g IV q 6-8 h for 3 days

aModified from references 3, 5, and I.
bConcomitant vaginal treatment may be helpful.

metronidazole, 500 mg orally b.i.d, for 7 days. If
failure occurs with either regimen, the patient
should be retreated with one of these standard regimens. Eighty-five percent of initial treatment failures will respond to a repeat single 2-g dose of
metronidazole. 10 If repeated failure occurs, the patient should be treated with a 2-g dose of metronidazole daily for 3-5 days. Compliance issues and
the possibility of reinfection should be addressed.
Cases of additional culture-documented treatment
failure should be managed in consultation with an
expert. The evaluation of such cases should include
a determination of the susceptibility of T. vaginalis
to metronidazole.
Metronidazole Resistance
In 1979, reports concerning the emergence of metronidazole-resistant strains of T. vaginalis were published. 11-13 Similar cases became clinically evident
in the United States and prompted the Centers for
Disease Control (CDC) to evaluate the susceptibility to metronidazole of isolates from women failing
at ]east 2 standard treatment regimens with metronidazole and in whom reinfection was unlikely because of the interim absence of coitus. 14 Although
methods for determining the sensitivity of T. vaginalis are not standardized, the testing procedures
identify 4 levels of metronidazole resistance: marginal, low, moderate, and high (Table 1). Aerobic
values for the mean lethal concentration (MLC), or
trichomonacidal level of metronidazole, appear to
correlate better with the clinical response to therapy
than the results of susceptibility testing done under
anaerobic conditions. Although there is considerable overlap in the MLC values of isolates from
responsive and unresponsive infections, an aerobic
MLC value of >100 g/ml is highly associated
with clinical resistance. 15

Patients with marginally resistant organisms respond well to repeat treatment with standard doses.
Increased resistance requires larger doses of metronidazole administered for longer periods (Table 1).
As noted above, patients with repeated treatment
failure should have cultures of their vaginal secretions and the T. vaginalis isolate tested for its susceptibility. This technique involves suspending a
swab of the vaginal secretions in modified Diamond’s medium followed by incubation at 35-37C
for >24 h. This culture medium should be prewarmed prior to inoculating the vaginal sample.
Once a positive culture is confirmed by a wet preparation of the original culture, a second prewarmed
culture tube should be inoculated and mailed by
overnight delivery service to a reference laboratory
capable of performing susceptibility testing. The
patient may be placed on intravaginal clotrimazole
in an attempt to ameliorate her symptoms while

awaiting the results of the T. vaginalis susceptibility testing.
Once the level of resistance is known, appropriate doses of metronidazole should be prescribed
(Table 1). Concurrent treatment with vaginal metronidazole has been recommended for patients with
isolates showing a high level of resistance. Prior to
the availability of 0.75% metronidazole vaginal
gel, 500-mg tablets of metronidazole (not enteric
coated) were used as vaginal suppositories. 4 Now,
5 g of gel (37.5 mg of metronidazole) may be used
intravaginally b.i.d, as an adjunct to high-dose oral
therapy in highly resistant cases.
Patients with significant resistance should be
evaluated for parasite persistence with a wet preparation of the vaginal secretions prior to discontinuing metronidazole therapy. If motile trichomonads
are noted, continued therapy is indicated or consideration of higher doses of metronidazole. Once the
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY
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parasite disappears from the wet preparation, a culperformed to ensure that low levels
of trichomonads do not remain. A follow-up appointment 6 weeks after therapy has been completed is also recommended. A repeat evaluation of
the vaginal secretions and trichomonas culture
should be performed at this time.
Oral absorption of metronidazole is almost complete. The drug is metabolized in the liver, and the
hydroxy metabolite may act synergistically with the
parent compound. Nausea and vomiting develop
less frequently during IV than oral therapy at normal-to-moderate doses. However, high doses may
lead to gastrointestinal side effects regardless of the
route of administration and may be due to the accumulation of the hydroxy metabolite. For this reason, hospitalization for the parenteral use of metronidazole for the treatment of resistant trichomonas
vaginitis is usually not recommended. Other manifestations of metronidazole toxicity include metallic taste, glossitis, stomatitis, urticaria, vertigo, convulsive seizures, and peripheral neuropathy.
Neurotoxicity appears to be a consistent problem
when high-dose treatment exceeds 3 or 4 days. 7
A number of similar nitroimidazole derivatives,
such as tinidazole and ornidazole, are available in
countries worldwide including Canada and the Bahamas, but not the United States. Although cross
resistance is common, it is often incomplete. These
alternative agents can be considered if susceptibility
studies suggest that certain metronidazole-resistant
infections can be effectively treated with these antimicrobials.
Several investigators have reported the use of
agents in addition to or other than metronidazole in
the treatment of resistant trichomonal infections.
Grossman and Galask 4 added a twice weekly 3%
acetic acid vaginal wash to their metronidazole regimen in successfully treating 2 patients with metronidazole-resistant trichomoniasis. In a different
case, a providone-iodine douche, 20 ml of a 10%
solution, given b.i.d, for 4 days (8 douches) and
repeated 2 weeks later for 2 days (4 douches) was
successful in eradicating a metronidazole-resistant
trichomonal infection that had previously been unresponsive to high-dose metronidazole and ornidazole. 16 Livengood and Lossick17 reported that the
routine use of a contraceptive suppository containing 100 mg of nonoxynol-9 resulted in complete
resolution of vaginal irritative symptoms after the
ture should be
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second episode of protected coitus. Further follow-up with wet preparations and culture documented resolution of the resistant trichomonas
vaginitis. The prior use of gentian violet, nitrofurantoin, chlorhexidine, clotrimazole, povidone-iodine, 3% acetic acid, and hydrogen peroxide had been unsuccessful. Oral mebandazole with
and without adjunctive vaginal mebendazole, although showing some in vitro activity against T.
vaginalis, failed to eradicate the parasite in 2 women
with resistant infection. 18 Lactobacillus immunotherapy using a vaccine of a lyophilisate of inactivated microorganisms of selected strains of Lactobacillus acidophilus, originally isolated from vaginal
secretions of patients with trichomoniasis, was unsuccessfully used in conjunction with high-dose metronidazole in an attempt to eradicate a metronidazole-resistant trichomonal infection. 19

RECURRENT BV
BV is considered the most common vaginal infection in women. It is a complex alteration of the
normal vaginal flora resulting in the replacement
of a predominantly HzOz-producing lactobacilli
melieu with a mixed flora of anaerobic bacteria,
Gardnerella vaginalis, and Mycoplasma hominis.
Common symptoms associated with BV include excessive vaginal discharge and vaginal malodor, although almost half of the women with this disorder
are asymptomatic. 2 BV is associated with a number of infectious reproductive sequelae including
upper genital tract infection, adverse pregnancy
outcomes, and postoperative infection, z Of several antibiotics that have been studied, including
sulfa vaginal creams, ampicillin, doxycycline, clindamycin, and metronidazole, the latter 2 appear to
be the most effective. Clindamycin and metronidazole can be administered either orally or intravaginally for the treatment of BV. 21-27 These agents are
associated with cure rates around 80% 4 weeks
following treatment.
Long-term recurrence rates are observed in patients with BV irrespective of" the treatment method.
Sobel et al. 28 noted that over half of cured patients
developed symptomatic clinical and laboratory
mainfestations of BV within 3 months of completing therapy. Up to 80% of women developed recurrent BV within 9 months of therapy in a Seattle
study. 29 The reasons for recurrence are not understood. One explanation suggests reinfection, either
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endogenously or by a male partner who is colonized
with BV-associated microorganisms. Data indicating that the treatment of male sexual partners fails
to reduce the incidence of recurrent BV argue
against this latter theory. 3 Other causes for recurrence may be explained by the persistence of BVassociated microorganisms. This persistence may
occur when the microorganisms are inhibited but
not killed, and pathogenic bacteria gain predominance because the normal, protective lactobacillusdominant flora has not been reestablished. 29’3
Cook et al., 31 in a study of 31 women with
recurrent BV, noted that relapse appeared to reflect
a failure of the complete normalization of the vaginal ecosystem without indicating resistance to metronidazole. Although the therapeutic implications of
their observations remain conjectural, more prolonged antimicrobial therapy could conceivably result in a lower recurrence rate because of a diminished anaerobic flora. Because failure to reestablish
a normal profile of lower-genital-tract flora is encountered, even among women considered clinically cured of BV, the restoration of a lactobacillidominant vaginal flora should be a central object of
therapy. Intravaginal inoculation of Lactobacillus
preparations could potentially improve outcome in
these patients. Unfortunately, over-the-counter
Lactobacillus preparations adhere poorly to vaginal
epithelial cells, making vaginal colonization unlikely. 2 In addition, most commercially available
Lactobaci]]us preparations do not contain the EgO eproducing strains known to be protective in the
vagina. Despite these observations, a diet associated with daily yogurt consumption has recently
been shown to decrease the risk for recurrent vulvovaginal candidiasis. 4 Since the postulated mechanism of action concerns colonization resistance by
lactobacilli of potential pathogens, a similar study
should be performed with respect to women with
recurrent

BV.

MANAGEMENT OF RECURRENT BV
The clinical approach to the management of women
with symptomatic recurrent BV should first concern confirming the diagnosis. Composite clinical
criteria (homogenous discharge, pH >4.5, clue
cells, positive whiff test) should be used initially
and confirmed by evaluating a Gram’s stain of vaginal secretions from the lateral vaginal sidewall.
Vulvovaginal candidiasis may be present in cases of
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TABLE 2. Treatment of recurrent BV
Antimicrobial agent
Metronidazole

Clindamycin
Clindamycin
Metronidazole
Amoxicillin/clavulanate

Metronidazole

Dose

Duration

500 mg p.o.b.i.d.
300 mg p.o.b.i.d.
2% vaginal cream qd
0.75% vaginal gel b.i.d.
500 mg p.o.t.i.d.
2 g p.o. q month

14 days
14 days
14 days
14 days
14 days
6 months

aMinimum duration of therapy. Discontinuation of antibiotic therapy is
based upon normalization of the vaginal secretions as documented by
microscopy of a wet preparation and Gram’s stain.
bprophylactic regimen.

recurrent BV and, if present, should be treated
prior to or concurrently with the institution of ther-

apy for BV. 3s
Once the diagnosis of BV is confirmed, treatment with an oral regimen of metronidazole or
clindamycin should then be undertaken (Table 2).
Although topical therapy is equally effective, it is
crucial to be able to evaluate the vaginal secretions
in women with recurrent or persistent symptoms to
ensure that microscopy of a wet preparation confirms the normalization of the vaginal flora. Topical medications interfere with performing a wet
preparation of the vaginal secretions; therefore, the
oral route of administration is preferred. Therapy
should be continued until an absence of clue cells is
documented by microscopy and confirmed by a
Gram’s stain of vaginal secretions from the lateral
vaginal sidewall. If, after 2 weeks of therapy, clue
cells persist, a change to an alternative antibiotic is
suggested. If both clindamycin and metronidazole
are ineffective, this author has used amoxicillin/
clavulanate with good results. Once the patient is
rendered asymptomatic and a follow-up evaluation
confirms the reestablishment of normal flora or at
least an absence of clue cells, intermittent singledose prophylaxis with 2 g of metronidazole once a
month can be considered. The 2-g dose of metronidazole is the only regimen proved to be effective
as single-dose therapy of BV. 22
The microflora may not revert to a lactobacilli

predominance during therapy or even immediately
after therapy because of the activity of clindamycin
or amoxicillin/clavulanate against lactobacilli. It
sometimes takes several weeks for the lactobacilli
predominance to appear in women after treatment
and cure by clinical criteria.
INFECTIOUS DISEASESIN OBSTETRICS AND GYNECOLOGY
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The sexual transmission of BV is controversial. 36
Generally, treatment of the male sexual partner of a
woman with BV is not recommended. However,
BV-associated bacteria can be isolated from the urine
and urethral scrapings of the male partners of
women with BV. Moreover, treatment of both the
patient and her partner for a longer time results in
significantly higher cure rates. 37 For these reasons,
concurrent therapy of the male sexual partner of the
patient with recurrent BV may be considered. In
addition, condom use should be recommended until such therapy is completed. Not only does condom use protect the patient from the potential of a
sexually transmitted reinfection, but it also avoids
alkalinization of the vagina by the ejaculate, which
may help in reestablishing a normal vaginal pH
and therefore normal vaginal flora.

SOPER
13.

vaginalis. Br J Vener Dis 55:351-353, 1979.
14. Meingassner JG, Thurner J: Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother 15:254-257, 1979.
15. Lossick JG, Muller M, Gorrell TE: In vitro susceptibility and doses of metronidazole required for cure in cases
of refractory vaginal trichomoniasis. J Infect Dis 153:
948-955, 1986.
16. Wong CA, Wilson PD, Chew TA: Povidone-iodine in

17.

18.

19.

REFERENCES
1. Kent HL: Epidemiology of vaginitis. Am J Obstet Gynecol 165:1168-1176, 1991.
2. Rein MF: Trichomonas vaginalis. In Mandell GL, Douglas RG, Jr, Bennett JE (eds): Principles and Practice of
Infectious Diseases. 3rd ed. New York: Churchill-Livingstone, pp 2115-2118, 1990.
3. Lossick JG: Treatment of sexually transmitted vaginosis/
vaginitis. Rev Infect Dis 12(suppl):S665-681, 1990.
4. Grossman JH, Galask RP: Persistent vaginitis caused by
metronidazole-resistant trichomonas. Obstet Gynecol 76:
521-522, 1990.
5. Mead PB, Gibson M, Schentag JJ, Ziemniak JA: Possi-

ble alteration of metronidazole metabolism by phenobarbital [Letter]. N Engl J Med 306:1490, 1982.
6.

7.

8.

9.

10.

11.

12.

246

20.

21.

22.

23.

24.

Ahmed-JushufIH, Murray AE, McKeownJ: Managing
trichomonal vaginitis refractory to conventional treatment
with metronidazole. Genitourin Med 64:25-29, 1988.
Lossick JG, Kent HL: Trichomoniasis: Trends in diagnosis and management. Am J Obstet Gynecol 165:12171222, 1991.
Sands RX: Pregnancy, trichomoniasis, and metronidazole: A novel dose schedule. Am J Obstet Gynecol 94:
350-355, 1966.
Peterson WF, Stauch JE, Ryder CD: Metronidazole in
pregnancy. Am J Obstet Gynecol 94:343-349, 1966.
Lyng J, Christensen J: A double-blind study of the value
of treatment with a single dose of tinidazole to partners to
females with trichomoniasis. Acta Obstet Gynaecol Scand
60:199-201, 1981.
CDC: 1993 Sexually transmitted diseases treatment guidelines. MMWR 42:70-72, 1993.
Muller M, Lossick JG, Gorrell TE: In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis. Sex Transm Dis
15:17-24, 1988.

INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY

Forsgren A, Forssman L: Metronidazole-resistant Trichomonas

25.

the treatment of metronidazole-resistant Trichomonas vaginalis. Aust NZ J Obstet Gynecol 30:169-171, 1990.
Livengood CI-I, Lossick JG: Resolution of’resistant vaginal trichomoniasis associated with the use of intravaginal
nonoxynol-9. Obstet Gynecol 78:954-956, 1991.
Pattman, RS, Sprott MS, Kearns AM, Earnshaw M:
Failure of mebendazole to cure trichomonal vaginitis resistant to metronidazole: Case reports. Genitourin Med
65:274-275, 1989.
van der Weiden RMF, van der Meijden WI, Bogchelman DI-I, Polderman AM: Treatment failure in trichomoniasis and persistance of the parasite after Lactobacillus
immunotherapy: Two case reports. Eur J Obstet Gynaecol Reprod Biol 34:171-178, 1990.
Eschenbach DA, Hillier S, Critchlow, Stevens C, De
Rousen T, Holmes KK: Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 158:
819-828, 1988.
Spiegal CA: Bacterial vaginosis. Clin Microbiol Rev
4:485-502, 1991.
Lugo-Miro VI, Green M, Mazur L: Comparison of
different metronidazole therapeutic regimens for bacterial
vaginosis. A meta-analysis. JAMA 268:92-95, 1992.
Schmitt C, Sobel JD, Meriwether C: Bacterial vaginosis:
Treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol 79:1020-1023, 1992.
Fischbach F, Petersen EE, Weissenbacher ER, Martius
J, et al.: Efficacy of clindamycin vaginal cream versus
oral metronidazole in the treatment of bacterial vaginosis.
Obstet Gynecol 82:405-410, 1993.
Hillier SL, Lipinski C, Briselden AM, Eschenbach DA:
Efficacy of intravaginal 0.75% metronidazole gel for the
treatment of bacterial vaginosis. Obstet Gynecol 81:963967, 1993.

CHIII, McGregor JA, Soper DE, Newton
E, Thomason JL: Bacterial vaginosis: Efficacy and safety
of intravaginal metronidazole treatment. Am J. Obstet

26. Livengood

Gynecol 170:759-764, 1994.
New approaches for the treatment of bacterial
vaginosis. Am J Obstet Gynecol 169:479-482, 1993.
28. Sobel JD, Schmitt C, Meriwether C: Long-term follow-up of patients with bacterial vaginosis treated with
oral metronidazole and topical clindamycin [Letter]. J
Infect Dis 167:783-784, 1993.
29. I-Iillier S, Holmes KK: Bacterial vaginosis. In Holmes
KK, Mardh P-A, Sparling PF (eds): Sexually Transmitted Diseases. 2nd ed. New York: McGraw-Hill, p 557,
27. Sweet RL:

1990.

BV AND TRICHOMONIASIS

J, Steiner JF, Deiss F, et al.: Comparison of
single dose vs. one-week course of metronidazole for
symptomatic bacterial vaginosis. JAMA 254:1046-1049,

30. Swedberg

1985.

31. Cook RL, Redondo-Lopez V, Schmitt C, Meriwether C,
Sobel jD: Clinical, moicrobiological, and biochemical
(actors in recurrent bacterial vaginosis. J Clin Microbiol
30:870-877, 1992.
32. Wood JR, et al.: In vitro and adherence of Lactobacillus

species to vaginal epithelial cells. Am J Obstet Gynecol
153:740-743, 1985.
33. Hughes VL, Hillier SL: Lactobacilli from non-prescription products used for the treatment of vaginitis. Obstet
Gynecol 75:244-248, 1990.

SOPER
34. Hilton E, Isenberg HD, Alperstein P, France K Borenstein MT: Ingestion of yogurt containing Lactobacillus

acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 116:353-357, 1992.
35. Redondo-Lopez V, Meriwether C, Schmitt, el al.: Vulvovaginal candidiasis complicating recurrent bacterial vaginosis. Sex Transm Dis 17:51-53, 1990.
36. Thomason JL, Gelbart SM, Scaglione NJ: Bacterial vaginosis: Current review with indications for asymptomatic
therapy. Am J Obstet Gynecol 165:1210-1217, 1991.
37. Mengel MB, Berg AO, Weaver CH, et al.: The effectiveness of single-dose metronidazole therapy for patients
and their partners with bacterial vaginosis. J Fam Pract
28:163-171, 1989.

INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY

MEDIATORS
of

INFLAMMATION

The Scientific
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Gastroenterology
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Hindawi Publishing Corporation
http://www.hindawi.com

Diabetes Research
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

International Journal of

Journal of

Endocrinology

Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com

Disease Markers

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Submit your manuscripts at
http://www.hindawi.com
BioMed
Research International

PPAR Research
Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Journal of

Obesity

Journal of

Ophthalmology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Evidence-Based
Complementary and
Alternative Medicine

Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Oncology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Parkinson’s
Disease

Computational and
Mathematical Methods
in Medicine
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

AIDS

Behavioural
Neurology
Hindawi Publishing Corporation
http://www.hindawi.com

Research and Treatment
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Oxidative Medicine and
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

